ライフサイエンスコーパス: IPD

1 IPD cases by additional serotypes covered by PPV23 incre

2 IPD changes were analyzed based on pretreatment serum AB

3 IPD counts at week t, conditional on the previous time p

4 IPD due to non-PCV13 serotypes increased by 30% compared

5 IPD hospitalizations declined by 73% between 2005 and 20

6 IPD hospitalizations declined by 79% and 67% for Maori a

7 IPD incidence among U.S. adults declined after PCV13 int

8 IPD incidence among US adults declined after PCV13 intro

9 IPD incidence declined among all adults.

10 IPD incidence in children <5 years was significantly low

11 IPD incidence in infants remains lower than rates report

12 IPD incidences declined after PCV introduction in both i

13 IPD leads to long-term cardiac damage, as evidenced by d

14 IPD meta-analysis was done using fixed effects models ad

15 IPD reduction of >=2 mm was found in 59% and 47.2% of th

16 IPD was obtained from 13 trials for 3,990 patients, pred

17 IPD were analysed using a one-stage approach.

18 IPD were sought from investigators with eligible trials.

19 aggregated data: OR, 0.5; 95%% CI, 0.3-1.01; IPD, unstratified: OR, 0.7; 95% CI, 0.5-0.97; IPD, strat

20 Here we use PF-06840003 (IPD), a hIDO1-selective inhibitor in clinical trials, as

21 Among 1082 IPD cases, we observed a 35.3% decrease (95% confidence

22 ar period, there were 3146 IPD cases and 150 IPD-related deaths (case fatality rate, 4.8%).

23 Post-PCV13 declines in serotype 19A IPD in persons aged <2 years (IRR, 0.23; CI, .13-.35) an

24 e the first release of the database in 2003, IPD-MHC has grown and currently hosts a number of specif

25 e era [adjusted IRR 0.08, 95% CI 0.03-0.22]; IPD caused by any serotype: 81.6 per 100 000 vs 15.3 per

26 The pooled PCV13 VE against serotype 3 IPD from the random-effects meta-analysis was 63.5% (95%

27 13 vaccine effectiveness (VE) for serotype 3 IPD in children.

28 t direct PCV13 protection against serotype 3 IPD in children.

29 During the 8-year period, there were 3146 IPD cases and 150 IPD-related deaths (case fatality rate

30 Of the 454 IPD cases with serotyped isolates, most were caused by n

31 There were 21 592 IPD cases during 2014-15 to 2017-18, including 20 108 (9

32 onducted a case-cohort study comprising 7926 IPD cases reported to the Norwegian Surveillance System

33 PD, unstratified: OR, 0.7; 95% CI, 0.5-0.97; IPD, stratified: OR, 0.8; 95% CI, 0.4-1.3).

34 Serotype 9N IPD cases also had higher comorbidity prevalence (748/10

35 s predicted to produce 31 (6, 76) additional IPD cases over five years and 83 (-10, 242) additional p

36 ted effect of current pediatric PCVs against IPD in the elderly.

37 timely 3-dose PCV coverage of >92%, all-age IPD in Australia almost halved (IRR, 0.53; 95% confidenc

38 All IPD isolates were vaccine serotypes.

39 lying conditions and were able to induce all IPD clinical presentations including bacteremic pneumoni

40 ounting for 36.1% of MR-IPD and 11.7% of all IPD isolates.

41 Although IPD and CAP occurred more frequently in patients with CD

42 Among IPD patients, the presence of pneumococcal gene slaA was

43 olerance is associated with meningitis among IPD patients.

44 d 180 degrees ) can be discriminated from an IPD of 0 degrees , with higher thresholds indicating bet

45 These results, based on an IPD meta-analysis of randomized trials, confirm the bene

46 n individual participant data meta-analysis (IPD-MA) on this subject.

47 We analyzed IPD cases from 2011 to 2016 for which a pneumococcal iso

48 We identified all CAP and IPD cases between 2008 and 2017 in a cohort of PLWH in a

49 nd typically eliminates it from carriage and IPD through herd immunity.

50 erotype-specific colonization prevalence and IPD incidence prior to and following childhood PCV immun

51 This systematic review and IPD analysis of six prospective cohort studies found no

52 uded three randomised controlled trials, and IPD was obtained for 341 participants.

53 The median age (interquartile range) at IPD due to serotypes 8 (59 [45-72] years) and 12F (56 [4

54 erotypes 8 and 12F were more likely to cause IPD in younger, healthier individuals and less likely to

55 allelic variants associated with 23 clinical IPD phenotypes.

56 irmed pneumococcal genotypes to the clinical IPD phenotype, relative to known clinical predictors, wa

57 Interview Survey, we estimated and compared IPD incidence in 2013-2014 and 2007-2008, by age and ser

58 We compared IPD patients with 33 healthy controls using z score anal

59 Public Health England conducts IPD surveillance and provides a national reference servi

60 ational surveillance of laboratory-confirmed IPD in England in infants aged <1 year diagnosed during

61 3 in immunocompetent adults seems to control IPD cases by PCV13 serotypes including serotype 3.

62 med a two-stage individual participant data (IPD) analysis comparing participants with subclinical hy

63 This individual participant data (IPD) meta-analysis (MA) assessed whether repeat prenatal

64 D PARTICIPANTS: Individual participant data (IPD) meta-analysis of 4 observational ICH studies incorp

65 ted a one-stage individual-participant data (IPD) meta-analysis searching PubMed and Embase to identi

66 tober 2016) and individual participant data (IPD) meta-analysis to test if dysregulation of the HPA a

67 to undertake an individual participant data (IPD) meta-analysis to: 1) assess the impact of ExCR on H

68 Individual participant data (IPD) meta-analysis was used to combine the African studi

69 total of 5,815 individual participant data (IPD) were available, of which 5,777 results (99.3%) were

70 Individual participant data (IPD) were sought from eligible RCTs.

71 alyses based on individual participant data (IPD) with meta-analyses of published AD, to establish wh

72 -effects model) and individual patient data (IPD) (logistic regression adjusted for confounders) were

73 stematic review and individual patient data (IPD) meta-analysis to explore macrolide benefit in subpo

74 This individual patient data (IPD) meta-analysis was performed to better understand th

75 cs, we performed an individual patient data (IPD) meta-analysis.

76 Individual-patient data (IPD) were pooled from 13 studies of 3,989 (94.1% aged <1

77 ontrol studies, and individual patient data (IPD) were requested from study authors for all types of

78 pathogenic variants and imprinting defects (IPD) are less affected than individuals with uniparental

79 antitis patients with implant pocket depths (IPD) of 5-8 mm underwent subgingival implant surface deb

80 riage transmission and disease with detailed IPD incidence data to test a range of hypotheses about t

81 t which a fixed interaural phase difference (IPD) of varphi (varied here between 30 degrees and 180 d

82 V13 impact on invasive pneumococcal disease (IPD) among adults with and without PCV13 indications.

83 ct effects on invasive pneumococcal disease (IPD) among adults with and without PCV13 indications.

84 tory data for invasive pneumococcal disease (IPD) and coded hospitalisations for non-invasive pneumoc

85 tory data for invasive pneumococcal disease (IPD) and coded hospitalizations for noninvasive pneumoco

86 eased risk of invasive pneumococcal disease (IPD) and community-acquired pneumonia (CAP), it is uncle

87 ) schedule on invasive pneumococcal disease (IPD) and pneumococcal community-acquired pneumonia (CAP)

88 cting against invasive pneumococcal disease (IPD) calls for alternate strategies to assess this.

89 ory data from invasive pneumococcal disease (IPD) cases affecting pediatric and adult population duri

90 Invasive pneumococcal disease (IPD) cases were identified through enhanced national sur

91 Invasive pneumococcal disease (IPD) cases were routinely reported to Public Health Engl

92 However, invasive pneumococcal disease (IPD) caused by PCV13-targeted serotypes still represents

93 d increase in invasive pneumococcal disease (IPD) caused by serotypes 8, 12F, and 9N; their clinical

94 Invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae serotype 2 (Sp2)

95 in preventing invasive pneumococcal disease (IPD) caused by vaccine serotypes.

96 Invasive pneumococcal disease (IPD) data for January 2012-December 2018 were retrieved

97 p decrease in invasive pneumococcal disease (IPD) due to the reduction in PCV serotypes.

98 h declines in invasive pneumococcal disease (IPD) due to vaccine-targeted serotypes in unimmunized ad

99 rveillance of invasive pneumococcal disease (IPD) from 2002 for baseline and appropriate later compar

100 Invasive pneumococcal disease (IPD) has declined significantly since the introduction o

101 festations of invasive pneumococcal disease (IPD) have thus far mainly been explained by patient char

102 incidence of invasive pneumococcal disease (IPD) in adults after the introduction of PCV13 in childh

103 carriage and invasive pneumococcal disease (IPD) in children and adults in Kilifi County.

104 st serotype 3 invasive pneumococcal disease (IPD) in children have shown inconsistent results. We per

105 pacts against invasive pneumococcal disease (IPD) in equivalent populations have not been performed.

106 idemiology of invasive pneumococcal disease (IPD) in individuals treated with immunosuppressants in a

107 incidence of invasive pneumococcal disease (IPD) in Taiwanese children.

108 Although the invasive pneumococcal disease (IPD) incidence due to vaccine serotypes (VT) has decline

109 e surveys and invasive pneumococcal disease (IPD) incidence in Kilifi, Kenya.

110 Invasive pneumococcal disease (IPD) is usually caused by a single serotype, and dual-se

111 ios comparing invasive pneumococcal disease (IPD), all-cause hospitalized pneumonia (ACHP), and pneum

112 m on cases of invasive pneumococcal disease (IPD), all-cause pneumonia (ACP), and otitis media (OM),

113 evere form of invasive pneumococcal disease (IPD), are largely unknown.

114 in preventing invasive pneumococcal disease (IPD), but deaths due to IPD still occur.

115 incidence of invasive pneumococcal disease (IPD).

116 damage during invasive pneumococcal disease (IPD).

117 hat can cause invasive pneumococcal disease (IPD).

118 7V mutation causing inherited prion disease (IPD) including Gerstmann-Straussler-Scheinker (GSS) dise

119 SF (so-called invasive pneumococcal disease; IPD) is uncertain.

120 Invasive pneumococcal diseases (IPDs) remain the leading cause of vaccine-preventable ch

121 ae-including invasive pneumococcal diseases (IPDs)-remain a significant public health concern worldwi

122 ing serotypes, there has not been a dominant IPD serotype post-vaccination as there was pre-vaccinati

123 and long-term cardiac damage incurred during IPD is due in part to cardiomyocyte necroptosis.

124 We estimated IPD incidence using Active Bacterial Core surveillance a

125 and interindividual contacts jointly explain IPD seasonality.

126 Most fatal IPD cases are currently not vaccine-preventable.

127 during and after Imprime administration for IPD changes (e.g., ABA, circulating immune complexes, co

128 We used nationwide surveillance data for IPD and a hierarchical Bayesian regression framework to

129 d (53/150 [35%]) had a known risk factor for IPD.

130 oeconomic disparities in hospitalization for IPD, ACP, and OM.

131 ied by us are also likely to be relevant for IPD.

132 In the PCV13 era, the RR for IPD was highest (significant) and the percentage of case

133 linical and microbiological surveillance for IPD among admissions of all ages at Kilifi County Hospit

134 ed through laboratory-based surveillance for IPD from 2005 through 2014 in South Africa was reviewed.

135 en after transmission of brain isolates from IPD A117V patients to the same mice.

136 f the research interventions than those from IPD (HRAD to HRIPD ratio = 0.95, p = 0.007), but the lim

137 AD were most likely to agree with those from IPD when the information size was large.

138 ished AD differed on average from those from IPD.

139 related proteins are covered by updates from IPD-IMGT/HLA and AFND, as well as newcomers VDJbase and

140 for Imprime-mediated immunopharmacodynamic (IPD) changes.

141 Consequently, the net change in IPD incidence is determined by the relative invasiveness

142 The change in IPD type was mostly due to a reduction in bacteremic pne

143 Decline in IPD and ACHP was attenuated among older adults and those

144 However, declines in IPD due to vaccine-targeted serotypes have been partiall

145 The declines in IPD in adults were most closely associated with the decl

146 Besides the decrease in IPD after 7-valent, then 13-valent PCV implementation, t

147 s have been partially offset by increases in IPD due to nonvaccine serotypes (NVTs).

148 e in cardiac sympathetic neural integrity in IPD patients occurs at a modest rate over 2 y on (11)C-H

149 onia cases and were particularly involved in IPD in patients with underlying conditions (35.8%).

150 At 24 weeks, a significant reduction in IPD (P = 0.01) was measured in the ChxC group (1.76 +/-

151 unding, and reported percentage reduction in IPD as 1 minus IRR.

152 s predicted to sustain current reductions in IPD cases in under-64-year-olds, but cases in 65+-year-o

153 The most significant rises in IPD incidence were for serotypes 8, 12F, and 24F.

154 ch measures the smallest detectable shift in IPD for a fixed frequency.

155 for the diagnostic and treatment strategy in IPD.

156 d 18 cancer systematic reviews that included IPD meta-analyses: all of those completed and published

157 Significantly lower IPD rates were seen after PCV13 introduction in adults a

158 tion of chlorhexidine chips had greater mean IPD reduction and greater percentile of sites with IPD r

159 linearly included in the model for the mean IPD counts along with an endemic component describing so

160 Low-ABA subjects typically showed minimal IPD changes except when ABA levels rose above 20 mug/ml

161 Vaccines were also devised to minimize IPD resistant to antibiotic treatment, despite the ecolo

162 -resistant invasive pneumococcal disease (MR-IPD) due to PCV7 serotypes (6B, 9V, 14, 19F, and 23F).

163 0000 population), accounting for 36.1% of MR-IPD and 11.7% of all IPD isolates.

164 is study, the impact of PCV7 and PCV13 on MR-IPD was prospectively assessed.

165 pean, North American and Australian national IPD.

166 Public Health England conducts national IPD surveillance.

167 as observed, although the impact on national IPD incidence varied internationally due to serotype rep

168 ; CI, .28-.44) differed from other 13v-non7v IPD (IRR, 0.73; CI, .35-1.48 for those aged <2 years and

169 In Indigenous people, baseline PCV13-non7v IPD incidence was 3-fold higher, amplified by a serotype

170 difficulty in fitting to past trends in NVT IPD in some age groups and inherent uncertainty about fu

171 pe IPD would be offset by a reduction in NVT IPD.

172 se in non-PCV13 (non-vaccine serotype [NVT]) IPD cases since 2014.

173 ults, serotypes 3 and 8 accounted for 36% of IPD cases.

174 2019; Sp2 increased in 2015 and caused 6% of IPD during 2015-2019, a 7-fold increase compared with 20

175 In 2016, NVTs constituted 72% of IPD cases in the elderly.

176 -PCV13 serotypes accounted for nearly 80% of IPD.

177 14, non-PCV13 serotypes accounted for 80% of IPD.

178 tion for the superior inhibition activity of IPD in hIDO1 with respect to hTDO.

179 ngs to other settings would depend on age of IPD onset, serotype profile, and timeliness of vaccinati

180 cant result in the only feasible analysis of IPD (unstratified model) (OR, 0.1; 95% CI, 0.0-0.4).

181 In the analysis of IPD, 2 regression models, stratified and unstratified by

182 mococcal epidemiology reducing the burden of IPD in children but also in adults by herd protection al

183 There were 517 cases of IPD (incidence: 19/100000 infants).

184 Surveillance identified 667 cases of IPD in 3 211 403 person-years of observation.

185 with meningitis in an exploratory cohort of IPD patients (n = 2054, p = 6.8 x 10(-6)), in an indepen

186 We compared the trajectory of decline of IPD due to PCV-targeted serotypes in adults with the dec

187 We aimed to describe children who died of IPD since PCV introduction in England and Wales.

188 The incidence of IPD and CAP among PLWH remains higher compared with the

189 By 2015-6, although incidence of IPD and PnCAP in children <5 years decreased by 38%, nei

190 By 2015-2016, although incidence of IPD and PnCAP in children aged <5 years decreased by 38%

191 work to estimate changes in the incidence of IPD associated with the introduction of PCV7 (2007) and

192 The incidence of IPD caused by serotype 19A in children aged 0-5 years wa

193 The relative increases in the incidence of IPD caused by specific NVTs did not differ appreciably b

194 n the total population, all-age incidence of IPD declined from 11.8 pre-PCV7 to 7.1 post-PCV13 (IRR 0

195 n the total population, all-age incidence of IPD declined from 11.8 pre-PCV7 to 7.1 post-PCV13 (IRR,

196 ed, with a 37% reduction in the incidence of IPD in elderly people (>=70 years) from 2012 to 2017.

197 erotype-specific changes in the incidence of IPD that occurred in different age groups, with or witho

198 ighly effective in reducing the incidence of IPD, especially as caused by serotype 19A, in Taiwanese

199 ional studies OBS reporting the incidence of IPD, non-invasive pneumococcal disease, hospitalizations

200 assessment for detrimental manifestations of IPD.

201 the population, whereas the small numbers of IPD cases observed in the younger age groups led to sign

202 tics, serotype distribution, and outcomes of IPD in infants, and to estimate the relative risk of PCV

203 structures reveal that the binding pocket of IPD in the active site in hIDO1 is much more flexible as

204 e successfully reduced the incidence rate of IPD from 17.8/100 000 in 2012 to 5.5/100 000 in 2017 amo

205 Incidence rates of IPD and CAP in PLWH were 111 and 1529 per 100 000 patien

206 We calculated the incidence rates of IPD and incidence rate ratios (IRRs) between years for d

207 Lower rates of IPD were seen with PCV7 (IRR 0.45, 95% CI 0.38-0.54) and

208 The overall reductions of IPD cases by PCV13 serotypes in children and adults were

209 in ambulatory care are at increased risk of IPD caused by a more diverse group of serotypes.

210 infant populations remain at higher risk of IPD in countries with established 13-valent PCV (PCV13)

211 The risk of IPD remains significantly higher in premature infants co

212 d to describe the changes in the spectrum of IPD and its clinical presentations after 13-valent PCV (

213 ion-based, nationwide active surveillance of IPD since 2009.

214 n school-age children and adults in terms of IPD and a small to negligible impact on infants and the

215 medical history, vaccination status, type of IPD, clinical features, and short-term evolution.

216 The marked winter seasonality of IPDs is a striking, but still enigmatic aspect of pneumo

217 o generate the marked seasonality typical of IPDs.

218 Data on IPD in adults were obtained from a nationwide surveillan

219 rs post PCV13, direct and indirect impact on IPD and PnCAP differed by age and between Indigenous and

220 rs post-PCV13, direct and indirect impact on IPD and PnCAP differed by age and between Indigenous and

221 England and Wales to describe the impact on IPD of 7-valent PCV (PCV7; introduced in 2006) and PCV13

222 rst year of life would have little impact on IPD or pneumococcal CAP cases or associated deaths at an

223 rhinovirus, also seemed to have an impact on IPD: RSV contributed 1.87% (CI 0.89%-3.08%) to pneumococ

224 The contribution of influenza on IPD during the 2009 pandemic also appeared to vary great

225 We analyzed the national data on IPDs from the Taiwan Centers for Disease Control between

226 For each prespecified outcome, IPD were analysed using a 1-stage approach.

227 se is discontinued in Kenya in 2022, overall IPD incidence will increase from 8.5 per 100 000 in 2022

228 k of PCV13-type, non-PCV13-type, and overall IPD in premature infants compared to term infants during

229 to carriage data from 2001/2002 and post-PCV IPD data to 2015, using vaccine coverage, mixing pattern

230 Pre-PCV IPD data and pre-/post-PCV colonization data were modell

231 n Indigenous people, baseline PCV13 non-PCV7 IPD incidence was 3-fold higher, amplified by a serotype

232 From pre- to post-PCV13 period, IPD rates declined 5%-48% and ACHP rates declined 4%-19%

233 Across study periods, IPD and ACHP rates increased with age (2-27 times higher

234 cases and 165 136 controls), and 27 provided IPD (5269 intrahepatic cholestasis of pregnancy cases).

235 Each trial provided IPD on HRQoL or exercise capacity (or both), with follow

236 of diverse NVTs in all settings' top-ranked IPD-causing serotypes emphasizes the urgent need for sur

237 loit pneumococcal seasonality to help reduce IPDs.

238 be less effective at targeting and reducing IPD in global populations than previous PCVs.

239 mplementation, the spectrum of the remaining IPD cases showed significant changes, with substantial d

240 PCV13 introduction, dual macrolide-resistant IPD decreased 74.1% (incidence 0.32/100000 in 2013).

241 o the IPD bound in the active site, a second IPD molecule was identified in an inhibitory site on the

242 used by a single serotype, and dual-serotype IPD is rare.

243 cessory genes identified among dual-serotype IPD isolates, four were common between isolate pairs.

244 assess factors associated with dual-serotype IPD, patient information obtained through laboratory-bas

245 model-predicted changes in vaccine-serotype IPD incidence rates were similar to the observed changes

246 With all serotyped IPD isolates covered by pneumococcal vaccines, our study

247 Overall, 170 Sp2 IPD cases were identified during 2009-2019; Sp2 increase

248 We describe a Sp2 IPD outbreak in Israel, in the 13-valent PCV (PCV13) era

249 Spectroscopic studies show that IPD exhibits 400-fold higher inhibition activity toward

250 The IPD incidence was estimated to have declined by 26.4% (9

251 The IPD-IMGT/HLA Database has provided a stable, highly acce

252 The IPD-MHC Database project collects and expertly curates s

253 The IPD-related mortality rate declined after 7-valent PCV i

254 by the short duration of follow-up, and the IPD meta-analysis is limited by the number of possible c

255 dy (as no control group was required for the IPD analysis) to assess associations between biochemical

256 hermore, only two RCTs were eligible for the IPD-MA; thus, the possibility to assess severe adverse n

257 Five cohort studies were included in the IPD meta-analysis of diurnal cortisol patterns with crys

258 med stratified analyses by HIV status in the IPD meta-analysis.

259 we describe the latest database release, the IPD-MHC 2.0 and discuss planned developments.

260 s reduced up to 25% and 11% respectively the IPD cases by PCV13 serotypes, showing a decrease of sero

261 In addition to the IPD bound in the active site, a second IPD molecule was

262 are most likely to be reliable and when the IPD approach might be required.

263 te robust clinical conclusions, and when the IPD approach will add considerable value.

264 To prevent the IPDs caused by ST2, we identified an effective ST2 neogl

265 a-analysis HRs could still differ from their IPD equivalents by a relative 10% in favour of the resea

266 A limitation of this IPD-MA was the risk of overestimation of the effect on p

267 neumococcal disease (IPD), but deaths due to IPD still occur.

268 previously shown to be directly relevant to IPD, as well as 18 uncharacterized genes.

269 ibution of pneumococcal genetic variation to IPD phenotype.

270 ation) was calculated for age-specific total IPD, PCV13 non-7-valent PCV (PCV7) serotypes, and PnCAP

271 ation) was calculated for age-specific total IPD, PCV13-non7v serotypes and PnCAP by Indigenous statu

272 PCV10-type IPD also declined in the post-vaccination era in unvacci

273 Incidence of non-PCV10-type IPD did not differ between eras.

274 ted in a substantial reduction in PCV10-type IPD in children and adults without significant replaceme

275 ne introduction and remained low (PCV10-type IPD: 60.8 cases per 100 000 in the prevaccine era vs 3.2

276 Among adults 19-64 years, PCV13-type IPD declined 57% (95% confidence interval [CI], -68% to

277 Among adults 19-64 years, PCV13-type IPD declined 57% (95%CI:-68,-43) in adults with immunoco

278 Among adults aged >=65 years, PCV13-type IPD decreased 68% (95% CI, -76% to -60%) in those with i

279 Among adults >=65 years, PCV13-type IPD decreased 68% (95%CI:-76,-60) in those with IC, 68%

280 Similar reductions in PCV13-type IPD in those with and without PCV13 indications suggest

281 Similar reductions in PCV13-type IPD in those with and without PCV13 indications suggest

282 mpact, as the small increase in vaccine-type IPD would be offset by a reduction in NVT IPD.

283 s a significant increase in non-vaccine type IPDs among adults, especially in those over 65 years.

284 act on reducing the overall and vaccine-type IPDs, but there was a significant increase in non-vaccin

285 d PCVs expected to minimize the post-vaccine IPD burden by applying Bayesian optimization to an ecolo

286 Significant effectiveness against VT IPD in infants was observed, although the impact on nati

287 decrease of 36.3% (95% CI 23.8-46.9) for VT IPD and an increase of 101.4% (95% CI 62.0-145.4) for no

288 ase of 101.4% (95% CI 62.0-145.4) for non-VT IPD.

289 indices were measured at every visit whereas IPD, recession, and bleeding on probing were assessed at

290 erformed to include data from RCTs for which IPD was not available.

291 for reducing infant-only or population-wide IPD, and identified potential benefits to including non-

292 d find 43 genes consistently associated with IPD across three geographically distinct WGS data sets o

293 f the genes we identified as associated with IPD, we find 23 genes previously shown to be directly re

294 this study we identify genes associated with IPD.

295 e RCTs (n = 5,161), and two contributed with IPD (n = 4,561).

296 Six cohorts met the inclusion criteria, with IPD on 23,038 participants.

297 5, there were 640 children hospitalized with IPD, 26589 for ACP, and 44545 for OM.

298 duction and greater percentile of sites with IPD reduction of >=2 mm as compared with bi-weekly supra

299 l from trial reports and compared these with IPD equivalents at both the trial and meta-analysis leve

300 Yearly IPD incidence in children younger than 5 years reduced s